Cite
The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer.
MLA
Aggarwal, Rahul, et al. “The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer.” Cancer (0008543X), vol. 119, no. 20, Oct. 2013, pp. 3636–43. EBSCOhost, https://doi.org/10.1002/cncr.28285.
APA
Aggarwal, R., Halabi, S., Kelly, W. K., George, D., Mahoney, J. F., Millard, F., Stadler, W. M., Morris, M. J., Kantoff, P., Monk, J. P., Carducci, M., & Small, E. J. (2013). The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer. Cancer (0008543X), 119(20), 3636–3643. https://doi.org/10.1002/cncr.28285
Chicago
Aggarwal, Rahul, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, et al. 2013. “The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer.” Cancer (0008543X) 119 (20): 3636–43. doi:10.1002/cncr.28285.